Skip to main content
BIOTRON LIMITED logo

BIOTRON LIMITED — Investor Relations & Filings

Ticker · BIT ISIN · AU000000BIT4 ASX Professional, scientific and technical activities
Open in API
Filings indexed 766 across all filing types
Latest filing 2013-07-25 Interim / Quarterly Rep…
Country AU Australia
Listing ASX BIT

About BIOTRON LIMITED

https://www.biotron.com.au

Biotron Limited is a clinical-stage company focused on the development of novel small molecule antiviral therapeutics. The company utilizes its proprietary ViroPore technology platform to design and develop drugs that target viroporins—a class of proteins found in a wide range of viruses that play critical roles in viral replication and the evasion of host immune responses. Biotron's primary clinical program centers on BIT225, a first-in-class inhibitor targeting the HIV-1 Vpu protein and the Hepatitis C virus p7 protein. The company aims to address unmet medical needs by developing treatments that can potentially eradicate viral reservoirs and improve patient outcomes. In addition to HIV and HCV, Biotron is exploring the application of its antiviral platform against other significant viral pathogens, including SARS-CoV-2, leveraging its expertise in ion channel-targeting chemistry to disrupt the viral life cycle.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 5 pages 40.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed quarterly financial data including consolidated cash flow statements, cash reconciliation, financing activities, and compliance statements. It is a quarterly report with substantive financial data and analysis for the quarter ended 30 June 2013. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. The content aligns with the definition of an Interim / Quarterly Report (IR), which requires comprehensive financial data for a period shorter than a full fiscal year. There is no indication that this is merely an announcement or certification, nor does it fit other categories such as Annual Report or Earnings Release. Therefore, the correct classification is IR. Q4 2013
2013-07-25 English
Presentation of HIV Trial Data to International AIDS Society 15 pages 2.8MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of clinical trial data for an antiviral drug BIT225, including study design, results, safety, and pharmacokinetics. It is addressed to the ASX and includes scientific data and analysis from a Phase 1b/2a clinical trial. The content is focused on presenting trial results and scientific findings rather than announcing a report or regulatory filing. The length is substantial (15,000 characters), and it contains detailed data and analysis, consistent with an investor or scientific presentation. There is no indication that this is an annual or interim financial report, audit, or earnings release. The document is a presentation of clinical trial data to an international conference and to investors or stakeholders. Therefore, the most appropriate classification is Investor Presentation (IP).
2013-06-30 English
PRESENTATION AT ASIA BIOTECH INVEST 2013 - HONG KONG 10 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a presentation by Biotron Limited's CEO at the Asia Biotech Invest 2013 conference. It includes detailed information about the company's clinical programs, drug development pipeline, recent trial results, and financial highlights. The content is structured as a presentation with forward-looking statements, clinical trial data, and company overview aimed at investors. There is no indication that this is an official annual or interim report, audit report, or regulatory filing. The document is not a transcript of a call, nor is it a voting result or management change announcement. It is clearly a detailed investor presentation focusing on financials, strategy, and market position, consistent with the definition of an Investor Presentation (IP). The document length (9141 characters) and content support this classification rather than a brief announcement or a full formal report.
2013-06-04 English
R&D Tax Incentive Refund 1 page 35.1KB
Regulatory Filings Classification · 95% confidence The document is a short announcement from Biotron Limited regarding receipt of an R&D Tax Incentive refund for the 2011/12 financial year. It is a brief notification about a government cash refund related to research and development expenditure. There are no financial statements, detailed financial data, or comprehensive report content. The document is only 1629 characters long and serves as an update on a specific financial event (receipt of a tax incentive refund). This fits best under a general regulatory announcement category rather than a full financial report or detailed filing. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2013-05-30 English
PRESENTATION OF HIV DATA AT INTERNATIONAL AIDS SOCIETY 2 pages 55.9KB
Regulatory Filings Classification · 95% confidence The document is a short announcement (2 pages) from Biotron Limited regarding the presentation of HIV trial data at an upcoming international conference. It discusses clinical trial results and upcoming presentations but does not contain detailed financial data, comprehensive analysis, or formal report content. The length is only 3447 characters, which is quite short and consistent with a press release or announcement rather than a full report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other formal financial filing. It is also not a regulatory filing or certification. The content focuses on clinical trial data presentation at a scientific conference, which is an update on company activities but not a financial or governance report. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2013-05-29 English
Presentation at European Liver Conference 2 pages 50.9KB
Investor Presentation Classification · 80% confidence The document is a short announcement (2929 characters) from Biotron Limited regarding a presentation at the European Liver Conference. It discusses clinical trial data and references that the data is available on the company's website. There are no financial statements, regulatory filings, or detailed financial analysis. The document is clearly a communication about a presentation of scientific/clinical data rather than a financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The closest fitting category is Investor Presentation (IP), as it relates to a presentation of data to an audience, although it is not a typical investor presentation but a scientific conference presentation. Given the options, the best classification is Investor Presentation (IP) with moderate confidence due to the nature of the content being a presentation of data at a conference.
2013-04-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.